A risk calculator predicting recurrence in lymph node metastatic penile cancer.
#PenileCancer
#uroonc
adjuvant treatments
inguinal lymph node metastases
penile cancer
recurrence
risk calculator
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
pubmed:
15
7
2020
medline:
7
2
2021
entrez:
15
7
2020
Statut:
ppublish
Résumé
To develop and externally validate a risk calculator for prediction of any cancer recurrence in patients with penile squamous cell carcinoma (pSCC) and inguinal lymph node metastases (ILNM), as to date no validated prognostic tool is available for patients with pSCC and ILNM. The development cohort included 234 patients from seven referral centres. The external validation cohort included 273 patients from two additional referral centres. Cox regression identified predictors of any recurrence, which were used to develop a risk calculator. The risk-calculator grouped the development and the validation cohorts according to the individual risk of any recurrence at 24 months (24m-R). Adjuvant treatment effects were tested on overall survival (OS) according to the derived tertiles, within the development and validation cohorts. Positive surgical margins, pN Adjuvant treatment planning is crucial in patients with pSCC with ILNM, where only weak evidence is available. The current tool proved to successfully stratify patients according to their individual risk, potentially allowing better tailoring of adjuvant treatments.
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
577-585Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 The Authors BJU International © 2020 BJU International Published by John Wiley & Sons Ltd.
Références
Parkin DM, Ferlay J, Curado MP et al. Fifty years of cancer incidence: CI5 I-IX. Int J Cancer 2010; 127: 2918-27
Verhoeven RH, Janssen-Heijnen ML, Saum KU et al. Population-based survival of penile cancer patients in Europe and the United States of America: no improvement since 1990. Eur J Cancer 2013; 49: 1414-21
Kao J, Lavaf A, Teng MS, Huang D, Genden EM. Adjuvant radiotherapy and survival for patients with node-positive head and neck cancer: an analysis by primary site and nodal stage. Int J Radiat Oncol Biol Phys 2008; 71: 362-70
Necchi A, Pond GR, Raggi D et al. Clinical outcomes of perioperative chemotherapy in patients with locally advanced penile squamous-cell carcinoma: results of a multicenter analysis. Clin Genitourin Cancer 2017; 15: 548-55.e3
Robinson R, Marconi L, MacPepple E et al. Risks and benefits of adjuvant radiotherapy after inguinal lymphadenectomy in node-positive penile cancer: a systematic review by the European Association of Urology Penile Cancer Guidelines Panel. Eur Urol 2018; 74: 76-83
NCCN - Evidence-Based Cancer Guidelines, Oncology Drug Compendium, Oncology Continuing Medical Education [Internet]. Available at: https://www.nccn.org/. Accessed March 2018
Professionals S-O. EAU Guidelines: Penile Cancer [Internet]. Uroweb. Available at: https://uroweb.org/guideline/penile-cancer/. Accessed March 2020
Necchi A, Lo Vullo S, Mariani L et al. Nomogram-based prediction of overall survival after regional lymph node dissection and the role of perioperative chemotherapy in penile squamous cell carcinoma: a retrospective multicenter study. Urol Oncol 2019; 37: 531.e7-e15
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-4
Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers. Eur Urol 2018; 73: 560-569.
Bandini M, Albersen M, Chipollini J et al. Optimizing the selection of candidates for neoadjuvant chemotherapy among node positive penile squamous cell carcinoma patients. BJU Int 2020; 125: 867-75
Canter DJ, Nicholson S, Watkin N, Hall E, Pettaway C, InPACT Executive Committee. The International Penile Advanced Cancer Trial (InPACT): rationale and current status. Eur Urol Focus 2019; 5: 706-9
Joshi SS, Handorf E, Strauss D et al. Treatment trends and outcomes for patients with lymph node-positive cancer of the penis. JAMA Oncol 2018; 4: 643-9
Chipollini J, Necchi A, Spiess PE. Outcomes for patients with node-positive penile cancer: impact of perioperative systemic therapies and the importance of surgical intervention. Eur Urol 2018; 74: 241-2
Svatek RS, Munsell M, Kincaid JM et al. Association between lymph node density and disease specific survival in patients with penile cancer. J Urol 2009; 182: 2721-7
Slaton JW, Morgenstern N, Levy DA et al. Tumor stage, vascular invasion and the percentage of poorly differentiated cancer: independent prognosticators for inguinal lymph node metastasis in penile squamous cancer. J Urol 2001; 165: 1138-42
Chaux A, Caballero C, Soares F et al. The prognostic index: a useful pathologic guide for prediction of nodal metastases and survival in penile squamous cell carcinoma. Am J Surg Pathol 2009; 33: 1049-57
Chipollini J, Azizi M, Lo Vullo S et al. Identifying an optimal lymph node yield for penile squamous cell carcinoma: prognostic impact of surgical dissection. BJU Int 2020; 125: 82-8
Lughezzani G, Catanzaro M, Torelli T et al. Relationship between lymph node ratio and cancer-specific survival in a contemporary series of patients with penile cancer and lymph node metastases. BJU Int 2015; 116: 727-33
Sri D, Sujenthiran A, Lam W et al. A study into the association between local recurrence rates and surgical resection margins in organ-sparing surgery for penile squamous cell cancer. BJU Int 2018; 122: 576-82
Ball MW, Schwen ZR, Ko JS et al. Lymph node density predicts recurrence and death after inguinal lymph node dissection for penile cancer. Investig Clin Urol 2017; 58: 20-6
Necchi A, Lo Vullo S, Perrone F et al. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. BJU Int 2018; 121: 348-56
Matulewicz RS, Flum AS, Helenowski I et al. Centralization of penile cancer management in the united states: a combined analysis of the american board of urology and national cancer data base. Urology 2016; 90: 82-8
Campbell RA, Slopnick EA, Ferry EK, Zhu H, Kim SP, Abouassaly R. Disparity between pre-existing management of penile cancer and NCCN guidelines. Urol Oncol 2017; 35: 531.e9-e14
Williams SB, Ray-Zack MD, Hudgins HK et al. Impact of centralizing care for genitourinary malignancies to high-volume providers: a systematic review. Eur Urol Oncol 2019; 2: 265-73
Davidsson S, Carlsson J, Giunchi F et al. PD-L1 expression in men with penile cancer and its association with clinical outcomes. Eur Urol Oncol 2019; 2: 214-21
Jacob JM, Ferry EK, Gay LM et al. Comparative genomic profiling of refractory and metastatic penile and nonpenile cutaneous squamous cell carcinoma: implications for selection of systemic therapy. J Urol 2019; 201: 541-8
Olesen TB, Sand FL, Rasmussen CL et al. Prevalence of human papillomavirus DNA and p16INK4a in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis. Lancet Oncol 2019; 20: 145-58
Necchi A, Eigl BJ, Yang ES et al. Gene expression profiling of advanced penile squamous cell carcinoma receiving cisplatin-based chemotherapy improves prognostication and identifies potential therapeutic targets. Eur Urol Focus 2018; 4: 733-6
Cocks M, Taheri D, Ball MW et al. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort. Hum Pathol 2017; 59: 55-61
Wang B, Gu W, Wan F et al. Prognosis of the 8th TNM staging system for penile cancer and refinement of prognostication by incorporating high risk human papillomavirus status. J Urol 2020; 203: 562-9
Clark PE, Spiess PE, Agarwal N et al. Penile cancer: clinical practice guidelines in oncology. J Natl Compr Canc Netw 2013; 11: 594-615
Azizi M, Aydin AM, Hajiran A et al. Systematic review and meta-analysis: is there a benefit in using neoadjuvant systemic chemotherapy in locally advanced penile squamous cell carcinoma? J Urol 2020; 203: 1147-55